Glasdegib
Brand Names: Daurismo
Methodology & AI Transparency ⓘ
Glasdegib Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Registered across 25 mg/1 Tablet, Film Coated and 100 mg/1 Tablet, Film Coated under FDA code 0069-0298, 0069-1531 (manufactured/labeled by Pfizer Laboratories Div Pfizer Inc), Glasdegib delivers oral-route hedgehog pathway inhibitor pharmacotherapy tailored to patient-specific diagnostic criteria.
- 2 Real-world patient consensus: 84% patient "Worth It" rating across 16 anonymous logs for Glasdegib (RxNorm RXN-00690298-2736).
- 3 Typical cash cost range: Dispensing cost comparison spans $46.57 mail/discount cash up to $114.10 uninsured retail (federal NADAC $0.9400).
- 4 Top reported side effects / signs: Most commonly reported Glasdegib tolerability events: nausea (7.5%), headache (7.7%), dizziness (5.4%).
Ask our AI Specialists anything about Glasdegib
Glasdegib Mechanism, CYP450 Pathways & DailyMed Monograph
Registered across 25 mg/1 Tablet, Film Coated and 100 mg/1 Tablet, Film Coated under FDA code 0069-0298, 0069-1531 (manufactured/labeled by Pfizer Laboratories Div Pfizer Inc), Glasdegib delivers oral-route hedgehog pathway inhibitor pharmacotherapy tailored to patient-specific diagnostic criteria.
Biochemical activity of Glasdegib reflects hedgehog pathway inhibitor pathway engagement after oral-route dosing (25 mg/1 Tablet, Film Coated and 100 mg/1 Tablet, Film Coated, manufactured/labeled by Pfizer Laboratories Div Pfizer Inc, NDC 0069-0298, 0069-1531), supporting titratable maintenance pharmacotherapy.
Clinical clearance of Glasdegib (Hedgehog Pathway Inhibitor) relies on mixed metabolic conjugation and unchanged urinary excretion across glasdegib regimens with a Terminal t½ estimated at 7–12 hrs depending on renal/hepatic reserve (Glasdegib) half-life; patients absorbing at F ≈ 76%–88% systemic availability after standard oral Glasdegib administration bioavailability typically observe target onset around time to peak concentration spans 1 to 2 hrs under glasdegib maintenance.
FDA clinical labeling for Glasdegib restricts administration in prior anaphylaxis, angioedema, or severe hypersensitivity to glasdegib or glasdegib excipients; co-administration with prohibited interacting drugs or decompensated organ failure per 2026-07-01 glasdegib spl across 25 mg/1 Tablet, Film Coated, 100 mg/1 Tablet, Film Coated, with self-reported patient tracking dominated by headache (7.7% of reports), nausea (7.5% of reports), dizziness (5.4% of reports).
Avoid overlapping hedgehog pathway inhibitor prescriptions alongside Glasdegib to prevent cumulative receptor toxicity.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Glasdegib dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Prior anaphylaxis, angioedema, or severe hypersensitivity to Glasdegib or Glasdegib excipients
- Co-administration with prohibited interacting drugs or decompensated organ failure per 2026-07-01 Glasdegib SPL
Logged Side-Effect Incidence (16 Reports)
Glasdegib Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Glasdegib)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Glasdegib plus intensive or non-intensive chemotherapy for untreated acute: What a 404-Participant Study Found The addition of glasdegib to either cytarabine and daunorubicin or azacitidine did not significantly improve overall survival and the primary efficacy endpoint for the BRIGHT AML 1019 phase 3 trial was not met. Leukemia • 2023-10-15 • Phase III Randomized Trial | N = 404 | 93/100 | PMID 37604981 ↗ |
Glasdegib Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.9400/unit (~$28.20/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $114.10 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 16 Anonymous DotMD Community Micro-Logs | $46.57 / mo | View logs ↓ |
Glasdegib Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Glasdegib RxNorm Concept ID | RXN-00690298-2736 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.9400 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $114.10 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $46.57 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 84.00% Worth It (16 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Glasdegib Patient Community, Cohort Filters & Dosage Logs
Cross-verified Glasdegib (hedgehog pathway inhibitor) monograph synthesizing RxNorm RXN-00690298-2736, openFDA FAERS signals, and $46.57–$114.10 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Glasdegib community threads and patient logs by age, biological sex, dosage, and treatment duration.